Browsing Tag
Prostate cancer
33 posts
Fusion Pharmaceuticals secures rights for advanced prostate cancer treatment from Heidelberg University and Euratom
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a trailblazer in the oncology sector specializing in the development of next-generation radiopharmaceuticals,…
Clarity Pharmaceuticals advances in SECuRE trial with promising prostate cancer treatment results
Clarity Pharmaceuticals (ASX: CU6), a clinical stage radiopharmaceutical company, announced significant progress in the SECuRE trial, marking a…
Curium wraps up patient enrollment in ECLIPSE trial in prostate cancer
Curium, a leading figure in the global nuclear medicine sector, has proudly announced the successful completion of patient…
Novartis gets Pluvicto EC approval for advanced prostate cancer
Novartis has received the approval of the European Commission (EC) for Pluvicto (lutetium (177Lu) vipivotide tetraxetan), a targeted…
Clinical-stage pharma firms Ayala Pharmaceuticals, Advaxis sign merger deal
Ayala Pharmaceuticals, a Nasdaq-listed clinical-stage oncology company, has entered into a merger deal with New Jersey-based biotech company…
Merck signs $290m deal with Orion Corporation for mCRPC candidate ODM-208
Merck has signed a global development and commercialization deal worth $290 million with Orion Corporation for the latter’s…
Liquid biopsy company ANGLE plc bags pharma services contract
UK-based liquid biopsy company ANGLE plc has won a pharma services contract worth up to $1.2 million from…
Cancer Targeted Technology gets NIH grant to support CTT1403 trial
Cancer Targeted Technology (CTT), a Seattle-based biotech company, has secured a grant of $1.44 million from the US…
GSK completes $5.1bn acquisition of Tesaro to boost oncology pipeline
GlaxoSmithKline (GSK), the British pharmaceutical powerhouse, has successfully concluded its $5.1 billion acquisition of Tesaro, a leading oncology-focused…
Novartis completes $2.1bn acquisition of Endocyte to boost cancer treatment capabilities
Swiss pharmaceutical giant Novartis has officially closed its $2.1 billion acquisition of US-based biopharma company Endocyte, solidifying its…